Sandoz Projects Long-Term Revenue and Margin Growth Through 2035 via Biosimilars

Key Facts

In a move reflecting optimism within the specialized pharmaceutical sector, Sandoz Group AG has issued a long-term outlook projecting sustained revenue and profit margin growth over the next decade. According to reports, the company is leveraging its biosimilar pipeline to drive expansion through 2035. This strategic positioning follows its corporate spin-off, focusing on high-margin markets to ensure long-term value creation for its shareholders.

The company benefits from a robust domestic economic environment, as market data recently showed strength in the Swiss manufacturing sector with the procure.ch Manufacturing PMI reaching 57.1 in early September, exceeding forecasts. This stability in the home market supports major players like Sandoz in executing long-term expansion plans within the high-margin global biosimilars industry.

Regarding market performance, the SDZNY stock stood at $84.34 at the close of September 4, 2026, having reached a day high of $85.36. Investors are now watching for sustained momentum given the current lack of immediate upcoming catalysts in the economic calendar, while monitoring support levels near the recent day low of $84.24.